Table 2. Therapeutic classes at the beginning and the end of the follow-up period and surgeries or laser procedures previous to or during the follow-up period.

Treatment modalities	Initial central scotomas (N=32)	Initial peripheral scotomas (N=34)	P-value
Therapeutic classes at the beginning of the follow-up period
Betaxolol	24 (75%)	22 (65%)	0.363a
Brimonidine	0 (0%)	4 (12%)	0.114b
Latanoprost	6 (19%)	8 (23%)	0.635a
Timolol	2 (6%)	0 (0%)	0.231b
Therapeutic classes at the end of the follow-up period
Betaxolol	15 (47%)	17 (50%)	0.800a
Brimonidine	3 (9%)	3 (9%)	1.000b
Latanoprost	12 (38%)	7 (21%)	0.129a
Betaxolol+latanoprost	1 (3%)	5 (15%)	0.198b
Brimonidine+latanoprost	1 (3%)	2 (5%)	1.000b
Surgical procedures
Cataract surgery	3 (9%)	4 (12%)
Filtering surgery	None	None
Laser procedure	None	None

^aχ²-test.

^bFisher exact test.